This bill aims to enhance access to treatment for patients suffering from serious mental illnesses by introducing specific definitions and regulations regarding the approval and dispensing of medications. It amends Chapter 176O of the General Laws to include a new definition of "serious mental illness," which encompasses various conditions such as bipolar disorders, major depressive disorders, schizophrenia, and post-traumatic stress disorder, as defined by the latest edition of the Diagnostic and Statistical Manual of Mental Disorders.

Additionally, the bill prohibits carriers and utilization review organizations from imposing prior authorization requirements, step therapy protocols, or any other restrictions that could delay the dispensing of FDA-approved drugs for treating serious mental illnesses. Similar provisions are included in Chapter 118E, ensuring that both the division and contracted entities cannot impose such restrictions on medications for serious mental illnesses. These amendments are designed to streamline access to necessary treatments and reduce barriers for patients in need of care.

Statutes affected:
Bill Text: 176O-1, 118E-8